Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics

Current Medical Research and Opinion

Volumn 27, Issue 1, 2011, Pages 71-78

  Curtis, Jeffrey R ^a   Hobar, Coburn ^b   Hansbrough, Kevin ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

Arthritis, rheumatoid; Injection site reactions; Patient reported outcomes; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT;

ADULT; ARTICLE; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FIBROMYALGIA; GENDER; HUMAN; INJECTION SITE BURNING; INJECTION SITE STINGING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NORMAL HUMAN; PREVALENCE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PAIN; PHYSICIANS; PREVALENCE; PROFESSIONAL COMPETENCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SYRINGES;

EID: 78650401491     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.534959     Document Type: Article

References (25)

1. Maini R, St Clair EW, Breedveld F, et al.; for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant metho-trexate: a randomised phase III trial. Lancet 1999;354:1932-39
2. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al.; for the TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radio-graphic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74
3. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45
4. Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corp 2010
5. Humira (adalimumab injection, solution) [prescribing information]. North Chicago, IL: Abbott Laboratories 2010
6. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recom-binant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
7. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009;36:898-906
8. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130:478-86
9. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52
10. Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005;64(Suppl 4):iv18-23
11. Furfaro N, Dewing K, Carlone J, et al. Nurse and physician differences in perception of patient knowledge and approach to education in the treatment of rheumatoid arthritis. Abstract presented at: American College of Rheumatology 2008 Annual Scientific Meeting; October 24-29, 2008; San Francisco, CA. Available at: http://acr.confex.com/acr/2008/webprogram/ Paper2043.html [Last accessed 13 May 2010]
12. New study highlights need for better interaction and education between rheumatoid arthritis patients and care providers [Reuters website]. October 28 2008. Available at http://www.reuters.com/article/pressRelease/ idUS140818\+28-Oct-2008\+PRN20081028 [Last accessed 13 May 2010]
13. Jolly H, Simpson K, Bishop B, et al. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. J Neurosci Nurs 2008;40:232-9
14. Katona C, Peveler R, Dowrick C, et al. Pain symptoms in depression: definition and clinical significance. Clin Med 2005;5:390-95
15. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007;61:1922-30
16. Ross AP. Tolerability, adherence, and patient outcomes. Neurology 2008;71(Suppl 3):S21-3
17. Lamour S, Bracher M, Nesbitt A. The PEG component of certolizumab pegol inhibits degranulation by stimulated mast cells. Abstract presented at: American College of Rheumatology 2009 Annual Scientific Meeting; October 17-21, 2009; Philadelphia, PA. Available at: http://acr.confex.com/ acr/2009/webprogram/ Paper13684.html [Last accessed 13 May 2010]
18. CIMZIA (certolizumab pegol) [prescribing information]. Smyrna GA: UCB Inc 2010
19. Kimberlin CL, Winterstein AG. Validity and reliability of measurement instruments used in research. Am J Health Syst Pharm 2008;65:2276-84
20. Worster A, Haines T. Advanced statistics: understanding medical record review (MRR) studies. Acad Emerg Med 2004;11:187-92
21. Keystone E, van der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum 2008;58:3319-29
22. Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann Rheum Dis 2009;68: 797-804
23. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96
24. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21
25. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-na?̈ve patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83